Hala Audi

Hala Audi is Chief Alliance Officer at Univercells and the CEO of Univercells’ advisory services business Unizima, a company dedicated to building biopharma infrastructure in emerging markets to meet rising demand for vaccines and biologics. Hala joined Univercells in January 2022 from a career in government and global public health. She has 20 years of international experience leading projects that focused on innovation in pharma economics, antimicrobial resistance and pandemic preparedness. As an arbitration lawyer and during her governmental career, Hala also gained a deep understanding of large public-private infrastructure and construction projects. She is a law graduate from Université Paris-II Assas and Columbia University and obtained her Masters in Public Administration by studying at Harvard Kennedy School and the LSE in London. About Univercells. Univercells transforms how biotech drugs are made so everyone, everywhere can get them. Through cutting-edge bioprocessing and technology, Univercells creates transformative platforms across drug discovery, development and delivery. Its focus is to drive accessiblity, affordability and sustainability to eliminate barriers for drug developers. Collaborating with biotech and pharmaceutical companies, Univercells paves the way for new vaccines and therapies targeting cancer, infectious diseases, and animal health. With world-leading and mission-aligned stakeholders like the European Investment Bank, the Global Health Investment Corporation and the Gates Foundation, Univercells is poised to make a difference on a global scale. About Unizima. Unizima is a biomanufacturing services and technology provider,bringing world class experience in biologics manufacturing to a range of clients in Africa and the Middle East, including development, bulk production and fill and finish. Flagship projects include the Institut Pasteur de Dakar’s Madiba vaccine facility; supporting the tech transfer to Senegal of a new Measle Rubella vaccine manufactured on Univercells Technologies equipment, funded by the Bill and Melinda Gates Foundation; acting as technical expert for a new vaccine manufacutring plant in Nigeria, and adivsing clients building new biologics facilities in the Arabian Gulf and North Africa.